In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET

In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET

Abstract Background Multiple myeloma (MM) is a disease of cancerous plasma cells in the bone marrow. Imaging-based timely determination of therapeutic response is critical for improving outcomes in MM patients. Very late antigen-4 (VLA4, CD49d/CD29) is overexpressed in MM cells. Here, we evaluated [...

Full description

Bibliographic Details
Main Authors: Anchal Ghai, Nikki Fettig, Francesca Fontana, John DiPersio, Mike Rettig, Julie O. Neal, Samuel Achilefu, Kooresh I. Shoghi, Monica Shokeen
Format: Article
Language:English
Published: SpringerOpen 2021-09-01
Series:EJNMMI Research
Subjects:
Therapy response
Very late antigen-4 (VLA4)
[64Cu]Cu-LLP2A
[18F]FDG
Multiple myeloma (MM)
Bortezomib (proteasome inhibitor) therapy
Online Access:https://doi.org/10.1186/s13550-021-00840-4

Internet

https://doi.org/10.1186/s13550-021-00840-4

Similar Items